Status:
COMPLETED
Dapagliflozin Effects on Mayor Adverse Cardiovascular Events in Patients With Acute Myocardial Infarction (DAPA-AMI)
Lead Sponsor:
Instituto Mexicano del Seguro Social
Conditions:
Acute Myocardial Infarction
Cardiovascular Morbidity
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
The actual evidence is solid about the use of de SGLT2-inhibitors in wide spectrum of cardiorenal targets, which has been shown in a great amount of randomized clinical trials compared with placebo. A...
Detailed Description
According with the World Health Organization, cardiovascular disease is the leading cause of mortality in the world, estimating 17.9 millions of deaths a year. The cardiovascular disease are a group o...
Eligibility Criteria
Inclusion
- Male and female IMSS eligible patients over 18 years of age
- Meet the criteria of the fourth definition of ST-segment elevation myocardial infarction
- Known with diabetes mellitus 2 or newly diagnosed diabetes according to ADA criteria
Exclusion
- Patients diagnosed with Type 1 Diabetes Mellitus
- Patients on chronic replacement therapy for renal function through peritoneal dialysis or hemodialysis
- Patients who have recently undergone immunosuppressive therapy
- Patients with a history of recurrent urinary tract infection
- Patients known to be allergic to SGLT-2 inhibitors
- Patients presenting as sudden aborted death
- Patients who after percutaneous coronary intervention require orotracheal intubation
Key Trial Info
Start Date :
January 26 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 20 2023
Estimated Enrollment :
188 Patients enrolled
Trial Details
Trial ID
NCT04717986
Start Date
January 26 2021
End Date
June 20 2023
Last Update
June 26 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Unidad Medica de Alta Especialidad No. 1, Bajío
León, Guanajuato, Mexico, 37260,